Jeffrey Varnes

ORCID: 0009-0009-6257-8063
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Synthesis and Catalytic Reactions
  • Mast cells and histamine
  • Immune cells in cancer
  • Cancer Research and Treatments
  • Cancer, Stress, Anesthesia, and Immune Response
  • Immune Cell Function and Interaction
  • Inflammatory mediators and NSAID effects
  • Cancer Immunotherapy and Biomarkers
  • Amino Acid Enzymes and Metabolism

Abstract Antitumor immunity can be hampered by immunosuppressive mechanisms in the tumor microenvironment, including recruitment of arginase (ARG) expressing myeloid cells that deplete l-arginine essential for optimal T-cell and natural killer cell function. Hence, ARG inhibition reverse immunosuppression enhancing antitumor immunity. We describe AZD0011, a novel peptidic boronic acid prodrug to deliver an orally available, highly potent, inhibitor payload (AZD0011-PL). demonstrate...

10.1158/1535-7163.mct-22-0431 article EN Molecular Cancer Therapeutics 2023-03-13

<div>Abstract<p>Anti-tumor immunity can be hampered by immunosuppressive mechanisms in the tumor microenvironment including recruitment of arginase (ARG) expressing myeloid cells which deplete L-arginine essential for optimal T cell and natural killer function. Hence, ARG inhibition reverse immunosuppression enhancing anti-tumor immunity. We describe AZD0011, a novel peptidic boronic acid prodrug to deliver an orally available, highly potent, inhibitor payload (AZD0011-PL)....

10.1158/1535-7163.c.6611322.v3 preprint EN 2024-09-16

<div>Abstract<p>Antitumor immunity can be hampered by immunosuppressive mechanisms in the tumor microenvironment, including recruitment of arginase (ARG) expressing myeloid cells that deplete l-arginine essential for optimal T-cell and natural killer cell function. Hence, ARG inhibition reverse immunosuppression enhancing antitumor immunity. We describe AZD0011, a novel peptidic boronic acid prodrug to deliver an orally available, highly potent, inhibitor payload (AZD0011-PL)....

10.1158/1535-7163.c.6611322.v1 preprint EN 2023-04-21
Coming Soon ...